Codis
Codis is a global CDMO specializing in commercial-scale spray drying, amorphous solid dispersions, and particle engineering for pharmaceutical, consumer health, OTC, and nutraceutical customers across 400,000+ sq ft of cGMP facilities in the US and UK.
- Company typePrivate
- Founded2025
- HeadquartersChesterfield, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Codis does
Codis is a global contract development and manufacturing organization (CDMO) specializing in commercial-scale spray drying, amorphous solid dispersions (ASDs), microencapsulation, continuous granulation, and particle engineering for the pharmaceutical, consumer health, OTC, and nutraceutical industries. The company operates 400,000+ square feet of cGMP manufacturing space across three sites — St. Louis, Missouri (corporate headquarters and microencapsulation/continuous granulation); Seymour, Indiana (large-scale aqueous spray drying and finished dose manufacturing); and Haverhill, United Kingdom (commercial spray drying, ASDs, organic and polymer chemistry). Codis holds FDA, EU GMP, and MHRA approvals and reports a 30+ year regulatory track record with zero critical observations across 11 audits since 2015, achieving MHRA lowest risk tier classification.
Codis's technology platform is built around GEA Niro spray dryers (TFD25, TFD250, TFD400, PSD-2, and the forthcoming PSD-4) augmented by proprietary continuous flow chemistry, spinning-disc solvent-free microencapsulation, and Process Analytical Technology (PAT)-enabled continuous manufacturing. The Haverhill site has continuously produced Sevelamer Hydrochloride and Carbonate APIs for over 20 years and is the world's most experienced manufacturer of this renal-care phosphate binder. Codis also markets functional ingredient sub-brands — Descote (microencapsulated vitamins and minerals), Destab (co-processed directly compressible minerals), MicroMask (taste-masked APIs), and Polysaccharide Iron Complex — distributed globally through regional partners.
The company generates revenue through project-based CDMO services (development, clinical, and commercial supply contracts) at custom pricing, supplemented by recurring ingredient product sales through its distribution network. Codis was formed in October 2025 through the integration of US-based Particle Dynamics and the Haverhill UK facility acquired from EUROAPI in June 2025, and is backed by growth equity from 1315 Capital, BroadOak Capital Partners, and Research Corporation Technologies. The Haverhill site is undergoing major capacity expansion including a new GEA PSD4 solvent-capable spray dryer supported by the UK government's Life Sciences Innovative Manufacturing Fund, which will make Codis the only UK CDMO offering commercial-scale solvent-based ASD spray drying when operational in 2027.
Codis firmographics
Firmographics- Name
- Codis
- Legal name
- Codis
- Website
- https://codis.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Codis is a global CDMO specializing in commercial-scale spray drying, amorphous solid dispersions, and particle engineering for pharmaceutical, consumer health, OTC, and nutraceutical customers across 400,000+ sq ft of cGMP facilities in the US and UK.
- Ownership category
- akta.pro rank
Codis industry classification
Industry- Product category
- Pharmaceutical Contract Development and Manufacturing (CDMO)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Canned, Frozen & Preservd Fruit, Veg & Food Specialties (2030)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where Codis is headquartered
LocationHeadquarters
- HQ city
- Chesterfield
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Codis business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Contract Manufacturing Services: Codis generates revenue through contract development and manufacturing organization (CDMO) services, providing spray drying, particle engineering, and manufacturing capabilities to pharmaceutical and healthcare companies on a project basis. Revenue is derived from development services, clinical manufacturing, and commercial supply contracts.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Codis product offering
Product offeringCore offering
Codis is a global contract development and manufacturing organization (CDMO) that provides commercial-scale spray drying (aqueous and solvent-based), amorphous solid dispersions (ASDs), microencapsulation, particle engineering, continuous granulation, organic and polymer chemistry, analytical services, and finished dosage form manufacturing to pharmaceutical, consumer health, OTC, and nutraceutical customers. In addition to CDMO services, Codis sells proprietary functional ingredient products including Sevelamer API, Descote® microencapsulated vitamins and minerals, Destab™ direct-compression minerals, MicroMask® taste-masked APIs, and Polysaccharide Iron Complex across three cGMP facilities in the United States and the United Kingdom.
Product overview
Codis is a global CDMO (contract development and manufacturing organization) offering a comprehensive portfolio of commercial-scale manufacturing services and functional ingredient products. The core platform consists of spray drying technologies (aqueous and solvent-based for amorphous solid dispersions), microencapsulation, continuous granulation, organic and polymer chemistry, analytical services, and final dosage form manufacturing. The product portfolio includes Sevelamer API (the world's leading supplier), Destab™ direct-compression calcium and magnesium carbonates, Descote® microencapsulated vitamins and minerals, MicroMask® taste-masked APIs, and Polysaccharide Iron Complex. These offerings are supported by regulatory, labeling, and packaging services across three cGMP facilities in the US and UK.
Differentiator
Problem solved
Functional benefit
Brands
- Destab™: Direct compression minerals product line including calcium and magnesium carbonates for pharmaceutical, consumer health, OTC, and nutraceutical markets.
- Descote®
- Polysaccharide Iron Complex
- MicroMask®
Products and services
- Sevelamer API
- Destab™
- Descote®
- MicroMask®
- MC-30120 Polysaccharide Iron Complex
- Spray Drying Services
- Microencapsulation Services
- Continuous Granulation
- Organic & Polymer Chemistry Services
- Analytical Services Comprehensive pharmaceutical testing including method development, transfer, validation, QC release testing, and stability testing. Features chemical analysis, physical characterization, and microbiological testing capabilities.
- Final Dosage Forms
- Labeling & Secondary Packaging
- Regulatory Support
Companies that use Codis
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Codis technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Codis partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and secondary.
- GEA (Process Division)coreMajor equipment supplier providing spray drying technology including GEA Niro TFD series dryers, PSD spray dryers, and the new PSD4 solvent-capable spray dryer. GEA equipment forms the core of Codis's manufacturing capabilities.
- IMCDsecondaryGlobal distribution partner serving Brazil for Codis functional products including Descote, Destab, and MicroMask product lines.
- SEPPICsecondaryRegional distribution partner serving France and Italy for Codis functional ingredient products.
- Savannah Fine ChemicalssecondaryRegional distribution partner serving South Africa for Codis functional products.
Scale indicators9 records
Recent moves9 records
Expansion highlights5 records
Codis competitors and assessment
Company assessmentDirect peers
- Hovione: Portugal-headquartered CDMO with deep specialization in spray drying for amorphous solid dispersions and particle engineering for oral solid dose. Most direct technology peer to Codis given overlapping spray drying, ASD, and pharmaceutical customer base.
- Lubrizol Life Science (Particle Sciences): Specialty CDMO offering particle engineering, spray drying, and complex formulation services for pharma and consumer health customers. Directly comparable niche particle engineering CDMO focus.
- Quotient Sciences: UK- and US-based CDMO focused on formulation development and spray dried dispersion services for pharma innovators. Closely comparable in ASD-focused spray drying offering and transatlantic operating model.
- EUROAPI: French active ingredients manufacturer and CDMO from which Codis acquired the Haverhill spray drying facility in June 2025. Continues to operate in adjacent API and CDMO spaces, making it a directly comparable European peer with overlapping spray drying heritage.
Broad incumbents
- Siegfried Holding: Swiss CDMO offering API and finished drug product manufacturing including spray drying capabilities. Operates at broader scale than Codis with overlapping pharmaceutical customer base.
- Aenova: European pharmaceutical CDMO with significant solid dose, nutraceutical, and consumer health manufacturing capacity. Competes with Codis in finished dosage forms and OTC/nutraceutical CDMO services.
- Cambrex: US-based small molecule API and finished dosage CDMO serving pharma innovators. Overlaps with Codis in solid oral dose and API manufacturing, though with less spray drying specialization.
- Lonza: Swiss-headquartered global CDMO with large-scale small molecule API, particle engineering, and oral dose capabilities. Competes with Codis for commercial spray drying and final dosage form manufacturing contracts from pharma innovators.
- Catalent (Novo Holdings): One of the largest global pharmaceutical CDMOs offering spray drying, ASD, softgel, and oral solid dose services. Broader portfolio but directly competes for commercial-scale ASD and bioavailability-enhancement contracts.
Regional players
- Seqens: French-headquartered pharmaceutical CDMO with API and specialty ingredient manufacturing capabilities. Overlaps with Codis in API and excipient manufacturing but is more regionally focused on the European market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Codis social profiles
Digital presenceCodis compliance and trust
Trust signalCompliance6 records
Codis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Codis leadership team
Management profileNumber of profiles
Profiles11 records
Codis funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Codis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Codis
What does Codis do?
Codis is a global contract development and manufacturing organization (CDMO) that provides commercial-scale spray drying (aqueous and solvent-based), amorphous solid dispersions (ASDs), microencapsulation, particle engineering, continuous granulation, organic and polymer chemistry, analytical services, and finished dosage form manufacturing to pharmaceutical, consumer health, OTC, and nutraceutical customers. In addition to CDMO services, Codis sells proprietary functional ingredient products including Sevelamer API, Descote® microencapsulated vitamins and minerals, Destab™ direct-compression minerals, MicroMask® taste-masked APIs, and Polysaccharide Iron Complex across three cGMP facilities in the United States and the United Kingdom.
Is Codis a public or private company?
Codis is a private company. It is classified as private equity controlled and is currently operating.
When was Codis founded?
Codis was founded in 2025. It employs 101 to 250 people.
Where is Codis based?
Codis is headquartered in Chesterfield, United States, in the North America region.
How does Codis make money?
One revenue line is on record: contract Manufacturing Services.
Who are Codis's main competitors?
Direct peers on record are Hovione, Lubrizol Life Science (Particle Sciences), Quotient Sciences and EUROAPI. Broad incumbents are Siegfried Holding, Aenova, Cambrex, Lonza and Catalent (Novo Holdings). Seqens is listed as a regional player.
Does Codis have an API?
No public API is recorded for Codis.
What industry is Codis in?
Codis's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325414 and its SIC code is 2030.